Saturday 17 October 2026 Export ABT’s income statement to Excel — free account

Abbott Laboratories

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024. In the quarter to June 2026, revenue grew 13.0%, EPS fell 47.5%, free cash flow grew 28.9% and total debt rose 142.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

104.88 0.20 +0.19%

Follow ABT

Alert me

Market cap: $181.1B
P/E: 33.9×
Fwd P/E: 22.9×
Dividend yield: 2.40%
F-score: 5/9
Altman Z: 5.61
Beneish M: −2.50
Dividend safety: 62/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total buys 4.40

Total sells 47.54

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	1	1	—	2	1	—	—	—	—	—
Sell	1	—	—	—	6	—	—	—	—	2	1	—

Insider Ownership 1.17%

Capital & Financial Ratios $m

Market Cap 181,140.00

Revenue 46,585.00

Net Income 5,425.00

Free Cash Flow 7,824.00

Net Debt 27,005.00

Current Ratio 1.38

Debt/Equity 0.63

P/E ratio 33.94

Fwd P/E 22.90

P/S ratio 3.92

P/B ratio 3.53

Past 5Y EPS Growth 8.27%

This Y EPS Growth 7.10%

Next Y EPS Growth 9.97%

Next Y revenue growth 13.24%

Next 5Y EPS Growth 9.33%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 43.16%

10-year low 10-year high

P/S against its own 10 years 28.82%

10-year low 10-year high

P/B against its own 10 years 27.31%

10-year low 10-year high

EV/Sales against its own 10 years 37.89%

10-year low 10-year high

EV/FCF against its own 10 years 21.93%

10-year low 10-year high

Dividends

Payout Ratio 0.82

Annual Dividend Rate 2.52

Annual Dividend Yield 2.40%

	total	individual payouts
2028	Powerpack
2027	Powerpack
2026	2.52	0.63 0.63 0.63 0.63
2025	2.36	0.59 0.59 0.59 0.59
2024	2.20	0.55 0.55 0.55 0.55
2023	2.55	0.51 0.51 0.51 0.51 0.51
2022	1.88	0.47 0.47 0.47 0.47
2021	1.80	0.45 0.45 0.45 0.45
2020	1.44	0.36 0.36 0.36 0.36
2019	1.28	0.32 0.32 0.32 0.32
2018	1.12	0.28 0.28 0.28 0.28
2017	1.06	0.27 0.27 0.27 0.27
2016	1.04	0.26 0.26 0.26 0.26

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	7,279	7,967	8,939	5,603
Receivables	6,565	6,925	7,929	8,599
Inventory	6,570	6,194	6,488	7,315
Other	—	—	—	—
	22,670	23,656	25,996	24,517

	2023	2024	2025	Q'26
Payables	4,295	4,195	4,240	4,794
ST’ Debt	1,080	1,500	3,033	3,005
Other	—	—	—	—
	13,841	14,157	16,496	17,814

Compound Annual Growth %

	10y	5y	3y
Sales	8.07%	5.08%	0.51%
Cash Flow	12.42%	3.90%	(0.05%)
Earnings	3.96%	7.74%	(2.01%)
Book Value	9.48%	9.84%	12.66%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	11,164	12,593	—	—	—
’25	10,358	11,142	11,369	11,459	44,328
’24	9,964	10,377	10,635	10,974	41,950
’23	9,747	9,978	10,143	10,241	40,109
’22	11,895	11,257	10,410	10,091	43,653
’21	10,456	10,223	10,928	11,468	43,075
’20	7,726	7,328	8,853	10,701	34,608

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	1,315	2,488	—	—	—
’25	1,417	2,047	2,787	3,315	9,566
’24	1,025	1,960	2,705	2,868	8,558
’23	1,143	1,203	1,877	3,038	7,261
’22	2,065	2,410	2,780	2,326	9,581
’21	2,637	2,128	2,701	3,067	10,533
’20	715	1,322	2,066	3,798	7,901

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	916	1,991	—	—	—
’25	933	1,545	2,291	2,626	7,395
’24	627	1,427	2,149	2,148	6,351
’23	763	696	1,317	2,283	5,059
’22	1,744	2,031	2,313	1,716	7,804
’21	2,240	1,715	2,240	2,453	8,648
’20	355	680	1,570	3,119	5,724

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.61	0.53	—	—	—
’25	0.76	1.01	0.94	1.01	3.72
’24	0.70	0.74	0.94	5.27	7.64
’23	0.75	0.78	0.82	0.91	3.26
’22	1.37	1.14	0.81	0.59	3.91
’21	1.00	0.66	1.17	1.11	3.94
’20	0.31	0.30	0.69	1.20	2.50

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	36.00	38.34	55.58	65.50	61.61	105.36	93.25	89.67	99.71	110.86	Analyst estimates 2026–2028 Powerpack
	High	45.79	57.77	74.92	89.24	115.14	142.60	139.83	115.83	121.64	141.23
People
People	Employees	75,000	99,000	103,000	107,000	109,000	113,000	115,000	114,000	114,000	115,000
	Revenue/emp, $m	0.28	0.28	0.30	0.30	0.32	0.38	0.38	0.35	0.37	0.39
Income, $m
Income, $m	Revenue	20,853	27,390	30,578	31,904	34,608	43,075	43,653	40,109	41,950	44,328
	Gross margin, %	56.39	54.70	58.45	58.53	56.65	56.97	56.15	55.18	55.41	56.42
	EBT	1,413	2,231	2,873	4,077	4,968	8,211	8,306	6,664	7,013	8,466
	EBT margin, %	6.78	8.15	9.40	12.78	14.36	19.06	19.03	16.61	16.72	19.10
	Net income	1,400	477	2,368	3,687	4,495	7,071	6,933	5,723	13,402	6,524
	Depreciation	1,518	3,933	3,310	3,014	3,327	3,538	3,267	3,243	3,218	3,116
Per share, $
Per share, $	Revenue	14.12	15.74	17.39	18.05	19.52	24.27	24.90	23.05	24.11	25.46
	Earnings	0.94	0.27	1.33	2.06	2.50	3.94	3.91	3.26	7.64	3.72
	Cash flow	2.17	3.20	3.58	3.47	4.46	5.93	5.47	4.17	4.92	5.49
	Capex	(0.76)	(0.65)	(0.79)	(0.93)	(1.23)	(1.06)	(1.01)	(1.27)	(1.27)	(1.25)
	Free cash flow	1.41	2.55	2.79	2.54	3.23	4.87	4.45	2.91	3.65	4.25
	Book value	14.03	17.87	17.48	17.70	18.61	20.30	21.05	22.31	27.53	30.31
	Shares, m	1,477	1,740	1,758	1,768	1,773	1,775	1,753	1,740	1,740	1,741
Valuation, ×
Valuation, ×	P/E	41.99	226.12	54.38	42.17	43.80	35.72	28.03	33.70	14.79	33.68
	P/S	2.77	3.73	4.16	4.81	5.61	5.80	4.40	4.77	4.69	4.92
	P/B	2.78	3.29	4.14	4.91	5.88	6.93	5.21	4.92	4.11	4.13
	EV/Sales	2.86	4.40	4.66	5.25	5.94	5.98	4.55	4.95	4.84	5.01
	EV/FCF	28.62	27.15	29.03	37.21	35.90	29.79	25.46	39.24	31.96	30.04
Cash, $m
Cash, $m	Operating cash flow	3,203	5,570	6,300	6,136	7,901	10,533	9,581	7,261	8,558	9,566
	Capex	(1,121)	(1,135)	(1,394)	(1,638)	(2,177)	(1,885)	(1,777)	(2,202)	(2,207)	(2,171)
	Free cash flow	2,082	4,435	4,906	4,498	5,724	8,648	7,804	5,059	6,351	7,395
Balance, $m
Balance, $m	Working capital	20,116	11,235	5,620	4,804	8,534	11,134	9,735	8,829	9,499	9,500
	Total debt	20,684	27,718	19,366	17,938	18,534	18,050	16,773	14,679	14,125	12,929
	Net debt	1,909	18,108	15,280	13,798	11,386	7,801	6,603	7,400	6,158	3,990
	Shareholders’ equity	20,717	31,098	30,722	31,301	33,003	36,024	36,905	38,827	47,901	52,771
Returns, %
Returns, %	ROA	2.98	0.74	3.30	5.46	6.40	9.57	9.27	7.75	17.33	7.76
	ROIC	8.36	1.99	4.96	6.28	7.54	12.02	12.01	8.76	7.89	8.87
	ROE	6.66	1.84	7.66	11.89	13.98	20.49	19.01	15.11	30.91	12.96

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ABT Abbott Laboratories	$181.1B	33.9×	22.9×	+13.02% (above 0%: growing)	−47.52% (below 0%: shrinking)	+28.87% (above 0%: growing)	57.71%	13.44%
MDT Medtronic PLC	$122.1B	23.2×	18.7×	+13.73% (above 0%: growing)	+41.98% (above 0%: growing)	+120.89% (above 0%: growing)	64.99%	18.08%	Compare
SYK Stryker Corporation	$112.5B	30.3×	24.1×	+9.42% (above 0%: growing)	+43.10% (above 0%: growing)	+14.12% (above 0%: growing)	68.27%	25.18%	Compare
BSX Boston Scientific Corporation	$64.0B	17.9×	17.8×	+7.53% (above 0%: growing)	+14.81% (above 0%: growing)	+13.29% (above 0%: growing)	70.71%	21.65%	Compare
EW Edwards Lifesciences Corporation	$50.8B	49.8×	30.7×	+13.63% (above 0%: growing)	−26.32% (below 0%: shrinking)	+142.84% (above 0%: growing)	77.46%	29.48%	Compare
DXCM DexCom, Inc.	$33.1B	33.2×	29.8×	+13.08% (above 0%: growing)	+41.30% (above 0%: growing)	−11.68% (below 0%: shrinking)	63.44%	24.33%	Compare
GEHC GE HealthCare Technologies Inc.	$31.8B	16.0×	14.4×	+5.75% (above 0%: growing)	+16.98% (above 0%: growing)	+750.00% (above 0%: growing)	41.17%	13.96%	Compare
PHG Koninklijke Philips N.V.	$24.9B	18.8×	11.2×	+2.94% (above 0%: growing)	+56.67% (above 0%: growing)	+49.74% (above 0%: growing)	49.31%	13.99%	Compare
STE STERIS plc	$21.9B	27.1×	23.6×	+7.30% (above 0%: growing)	+13.89% (above 0%: growing)	−14.36% (below 0%: shrinking)	45.84%	19.15%	Compare
Median of peers	$41.9B	25.2×	21.2×	+8.48%	+29.14%	+31.93%	64.22%	20.40%

All 149 Medical Devices stocks →

Abbott Laboratories (ABT) key facts

Concern: Net income was $6.5 billion, or $3.72 per share (basic), a net margin of 14.7%.
Strength: Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.
Abbott Laboratories (ABT) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, ABT traded at $104.88, a market capitalization of $181.1 billion.
At that price the stock trades at 33.9× trailing-twelve-month earnings and 3.9× sales; its P/E is higher than 43% of its own readings over the past ten years.
Abbott Laboratories pays an annual dividend of $2.52 per share, a yield of 2.40%, with a payout ratio of 81.6%.
Return on equity was 13.0% and debt-to-equity 0.63.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 5.61 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Financial Analysis (summary)

Updated 29 September 2026

Abbott’s latest annual results show revenue growth alongside higher operating income, operating cash flow and free cash flow. Annual net income and diluted EPS were lower than the preceding year, while gross, operating and pre-tax margins increased. Capital returns included dividends and net share repurchases, and the weighted average share count was lower over the longer comparison period.

The latest quarter showed higher revenue and free cash flow than both the prior quarter and the year-earlier quarter, while diluted EPS was lower on both comparisons. Net debt rose sharply during the first half of the year. Current valuation multiples were below the company’s own historical medians in several measures but above the supplied industry medians where comparisons were available.

Read the full analysis →